CD39 AND PLATELET REACTIVITY IN ARTERIAL AND VENOUS THROMBOSIS

动脉和静脉血栓形成中的 CD39 和血小板反应性

• 批准号: 7604159
• 负责人: JORGE R KIZER
• 金额: $ 0.02万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604159
• 关键词: Acute; Address; Atherosclerosis; Blood; Blood Platelets; Computer Retrieval of Information on Scientific Projects Database; Cross-Sectional Studies; Funding; Grant; Human; Institution; Pathogenesis; Patients; Phase; Platelet Activation; Protein Isoforms; RNA Splicing; Research; Research Personnel; Resources; Role; Source; Testing; Therapeutic; Thromboembolism; Thrombosis; United States National Institutes of Health; Variant; Venous; Venous Thrombosis; acute coronary syndrome; novel therapeutics

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose a cross-sectional study of younger patients with acute coronary syndromes (ACS) or spontaneous venous thromboembolism (VTE) and healthy controls to address 4 specific aims: 1) Investigate whether reduced CD39 activity, and increased expression of CD39 splice variant 1.5, are associated with ACS in patients with premature atherosclerosis, both in the acute and convalescent phases; 2) Evaluate relationship between CD39 activity, CD39 isoform expression, and spontaneous VTE, both in the acute and convalescent phases; 3) Determine whether, and to what degree, increased platelet reactivity is associated with spontaneous VTE, and to compare its extent to that in ACS; 4) Assess the role of blood-borne TF in premature arterial and venous thrombosis. The significance of this study is that it addresses potentially central molecules in human thromboregulation and thrombogenesis. A role for CD39 deficiency in human thrombosis would spur additional study into determinants of this reduced activity, and provide a strong rationale for testing soluble CD39 for therapeutic application. Novel therapeutic options could be opened by determining the role of blood-borne TF in the pathogenesis of premature arterial and venous thrombosis. Last, by demonstrating whether, and to what extent, platelet activation is involved in VTE, the study could re-focus research appropriately, with clear therapeutic implications.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 我们建议对年轻的急性冠状动脉综合征（ACS）或自发静脉血栓栓塞（VTE）和健康对照组进行横断面研究，以解决4个具体目标：1）在急性和康复阶段的过早动脉粥样硬化患者中与AC相关。 2）评估CD39活性，CD39同工型表达和自发VTE之间的关系，无论是在急性和康复阶段中； 3）确定血小板反应性的增加以及在何种程度上与自发的VTE相关，并将其与AC中的程度进行比较； 4）评估血源性TF在早产和静脉血栓形成中的作用。 这项研究的意义在于，它解决了人体势能调节和血栓形成中潜在的中央分子。 CD39缺乏在人类血栓形成中的作用将刺激其降低活性的决定因素，并为测试可溶性CD39的治疗应用提供了强大的理由。可以通过确定血源性TF在早产和静脉血栓形成的发病机理中的作用来打开新颖的治疗选择。最后，通过证明VTE是否涉及血小板激活以及在何种程度上，该研究可以适当地重新对焦研究，并具有明显的治疗意义。